Association between selenium nutritional status and metabolic risk factors in men with visceral obesity

Journal of Trace Elements in Medicine and Biology

Volumn 27, Issue 2, 2013, Pages 112-116

  Mutakin, ^a,b   Meiliana, Anna ^c   Wijaya, Andi ^c   Kobayashi, Kenji ^a   Yamazaki, Chiho ^a   Kameo, Satomi ^a   Nakazawa, Minato ^a   Koyama, Hiroshi ^a  

^a GUNMA UNIVERSITY   (Japan)

^b PADJADJARAN UNIVERSITY   (Indonesia)

^c Prodia Clinical Laboratory   (Indonesia)

Author keywords

Adipocytokines; Metabolic risk factors; Metabolic syndrome; Obesity; Selenium

Indexed keywords

FATTY ACID BINDING PROTEIN 4; GLUTATHIONE PEROXIDASE 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; SELENIUM;

ABDOMINAL OBESITY; ADULT; ARTICLE; ASIAN; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; ENZYME ACTIVITY; HUMAN; INDONESIAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NUTRITIONAL STATUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADIPOKINES; ADULT; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; FATTY ACIDS; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; NUTRITIONAL STATUS; OBESITY, ABDOMINAL; RISK FACTORS; SELENIUM; TRIGLYCERIDES;

EID: 84875114877     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2012.09.006     Document Type: Article

References (41)

1. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365(9468):1415-1428.
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.
3. Grundy S.M., Hansen B., Smith S.C., Cleeman J.I., Kahn R.A. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004, 109(4):551-556.
4. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366(9491):1059-1062.
5. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114(12):1752-1761.
6. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 2006, 580(12):2917-2921.
7. Matsuzawa Y., Funahashi T., Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999, 892:146-154.
8. Coll B., Cabre A., Alonso-Villaverde C., Lazaro I., Aragones G., Parra S., et al. The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis 2008, 199(1):147-153.
9. Beaglehole R., Jackson R., Watkinson J., Scragg R., Yee R.L. Decreased blood selenium and risk of myocardial infarction. Int J Epidemiol 1990, 19(4):918-922.
10. van de Vijver L.P., Kardinaal A.F., Grobbee D.E., Princen H.M., van Poppel G. Lipoprotein oxidation, antioxidants and cardiovascular risk: epidemiologic evidence. Prostaglandins Leukot Essent Fatty Acids 1997, 57(4-5):479-487.
11. Steinbrenner H., Sies H. Protection against reactive oxygen species by selenoproteins. Biochim Biophys Acta 2009, 1790(11):1478-1485.
12. Rayman M.P. Food-chain selenium and human health: emphasis on intake. Br J Nutr 2008, 100(2):254-268.
13. Molnar J., Garamvolgyi Z., Herold M., Adanyi N., Somogyi A., Rigo J. Serum selenium concentrations correlate significantly with inflammatory biomarker high-sensitive CRP levels in Hungarian gestational diabetic and healthy pregnant women at mid-pregnancy. Biol Trace Elem Res 2008, 121(1):16-22.
14. Witkowska A.M., Kuryliszyn-Moskal A., Borawska M.H., Hukalowicz K., Markiewicz R. A study on soluble intercellular adhesion molecule-1 and selenium in patients with rheumatoid arthritis complicated by vasculitis. Clin Rheumatol 2003, 22(6):414-419.
15. Salonen J.T., Salonen R., Seppanen K., Kantola M., Parviainen M., Alfthan G., et al. Relationship of serum selenium and antioxidants to plasma lipoproteins, platelet aggregability and prevalent ischaemic heart disease in Eastern Finnish men. Atherosclerosis 1988, 70(1-2):155-160.
16. Puchau B., Zulet M.A., Gonzalez de Echavarri A., Navarro-Blasco I., Martinez J.A. Selenium intake reduces serum C3, an early marker of metabolic syndrome manifestations, in healthy young adults. Eur J Clin Nutr 2009, 63(7):858-864.
17. Rayman M.P. The importance of selenium to human health. Lancet 2000, 356(9225):233-241.
18. Takahashi K., Avissar N., Whitin J., Cohen H. Purification and characterization of human plasma glutathione peroxidase: a selenoglycoprotein distinct from the known cellular enzyme. Arch Biochem Biophys 1987, 256(2):677-686.
19. Lee Y.S., Kim A.Y., Choi J.W., Kim M., Yasue S., Son H.J., et al. Dysregulation of adipose glutathione peroxidase 3 in obesity contributes to local and systemic oxidative stress. Mol Endocrinol 2008, 22(9):2176-2189.
20. Al Mutairi S.S., Mojiminiyi O.A., Shihab-Eldeen A.A., Al Sharafi A., Abdella N. Effect of smoking habit on circulating adipokines in diabetic and non-diabetic subjects. Ann Nutr Metab 2008, 52(4):329-334.
21. World Medical Association W. Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. Volume 2010 2008, World Medical Association, Inc., Berlin.
22. Fujita K., Nishizawa H., Funahashi T., Shimomura I., Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J 2006, 70(11):1437-1442.
23. Maebuchi M., Machidori M., Urade R., Ogawa T., Moriyama T. Low resistin levels in adipose tissues and serum in high-fat fed mice and genetically obese mice: development of an ELISA system for quantification of resistin. Arch Biochem Biophys 2003, 416(2):164-170.
24. Richieri G.V., Anel A., Kleinfeld A.M. Interactions of long-chain fatty acids and albumin: determination of free fatty acid levels using the fluorescent probe ADIFAB. Biochemistry 1993, 32(29):7574-7580.
25. World Health Organization. Standard Operating Procedure for Clinical Chemistry. Volume 2010: WHO Regional Office for South-East Asia 2010 All rights reserved; 2010.
26. Abdulah R., Katsuya Y., Kobayashi K., Nakazawa M., Nara M., Murakami M., et al. Effect of sodium selenite supplementation on the levels of prostacyclin I(2) and thromboxane A(2) in human. Thromb Res 2007, 119(3):305-310.
27. Paglia D.E., Valentine W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967, 70(1):158-169.
28. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome IDF Communication; 2006. p 11.
29. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna; 2008.
30. Vinceti M., Wei E.T., Malagoli C., Bergomi M., Vivoli G. Adverse health effects of selenium in humans. Rev Environ Health 2001, 16(4):233-251.
31. Persson-Moschos M., Alfthan G., Akesson B. Plasma selenoprotein P levels of healthy males in different selenium status after oral supplementation with different forms of selenium. Eur J Clin Nutr 1998, 52(5):363-367.
32. Alfthan G., Xu G.L., Tan W.H., Aro A., Wu J., Yang Y.X., et al. Selenium supplementation of children in a selenium-deficient area in China: blood selenium levels and glutathione peroxidase activities. Biol Trace Elem Res 2000, 73(2):113-125.
33. Jossa F., Trevisan M., Krogh V., Farinaro E., Giumetti D., Fusco G., et al. Serum selenium and coronary heart disease risk factors in southern Italian men. Atherosclerosis 1991, 87(2-3):129-134.
34. Koyama H., Abdulah R., Ohkubo T., Imai Y., Satoh H., Nagai K. Depressed serum selenoprotein P: possible new predicator of increased risk for cerebrovascular events. Nutr Res 2009, 29(2):94-99.
35. Puchau B., Zulet M.A., Hermsdorff H.H., Navarro-Blasco I., Martinez J.A. Nail antioxidant trace elements are inversely associated with inflammatory markers in healthy young adults. Biol Trace Elem Res 2010, 133(3):304-312.
36. Harrington J.R. The role of MCP-1 in atherosclerosis. Stem Cells 2000, 18(1):65-66.
37. de la Sierra A., Larrousse M. Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension. J Hum Hypertens 2010, 24(6):373-379.
38. Krusinova E., Pelikanova T. Fatty acid binding proteins in adipose tissue: a promising link between metabolic syndrome and atherosclerosis?. Diabetes Res Clin Pract 2008, 82(Suppl. 2):S127-S134.
39. Maeda K., Cao H., Kono K., Gorgun C.Z., Furuhashi M., Uysal K.T., et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005, 1(2):107-119.
40. Makowski L., Hotamisligil G.S. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 2005, 16(5):543-548.
41. Ma W.Y., Li H.Y., Hung C.S., Lin M.S., Chiu F.C., Lin C.H., et al. Metabolic syndrome defined by IDF and AHA/NHLBI correlates better to carotid intima-media thickness than that defined by NCEP ATP III and WHO. Diabetes Res Clin Pract 2009, 85(3):335-341.